EU Clinical Trial 2018-002145-11

A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4- Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment  Mar 21, 2019

Main objective of the trial: The primary objective of this study is to evaluate the efficacy of natalizumab extended interval dosing (EID) in subjects who have previously been treated with natalizumab standard interval dosing (SID) for at least 12 months, in relation to continued SID treatment. El objetivo principal del estudio es evaluar la eficacia del IAA de natalizumab en sujetos que hayan sido tratados previamente con un IEA de natalizumab durante al menos 12 meses, en relación con un tratamiento de IEA continuado.